Third Harmonic Earnings Reports

In Q4 2024, Third Harmonic Bio recorded no revenue and a net loss of $13.1 million or -$0.29 per share. The increase in expenses was driven by continued investment in the THB335 program. The company ended the quarter with $285.1 million in cash and cash equivalents and continues its strategic review process.

Third Harmonic Bio reported a net loss of $13.8 million for the third quarter of 2024, with cash and cash equivalents totaling $296.1 million as of September 30, 2024.

Third Harmonic Bio reported a net loss of $10.7 million for the second quarter of 2024, with cash and cash equivalents totaling $255.3 million as of June 30, 2024. The company believes its current cash will fund operations through at least 2026. Clinical results for the THB335 Phase 1 SAD/MAD clinical trial are expected in 1Q'25.

Third Harmonic Bio reported a net loss of $7.9 million for the first quarter of 2024, with cash and cash equivalents totaling $262.8 million as of March 31, 2024. The company believes its cash will be sufficient to fund operations through at least 2026. They also announced U.S. FDA clearance of its Investigational New Drug application for THB335.

Third Harmonic Bio reported a net loss of $6.8 million for the fourth quarter of 2023, with cash and cash equivalents totaling $269.1 million as of December 31, 2023. The company believes its cash will fund operations through at least 2026.

Third Harmonic Bio reported a net loss of $7.3 million for the third quarter of 2023, with cash and cash equivalents totaling $273.9 million as of September 30, 2023. The company is on track to file a U.S. IND application for THB335 and initiate clinical studies in 1H'24.

Third Harmonic Bio reported a net loss of $7.6 million for the second quarter of 2023. The company's cash and cash equivalents totaled $278.1 million as of June 30, 2023, which is expected to fund operations through at least 2025. They also announced the next-generation product candidate, THB335.

Third Harmonic Bio reported a net loss of $9.1 million for the first quarter ended March 31, 2023. The company's cash and cash equivalents totaled $282.2 million as of March 31, 2023, which is expected to fund operations for at least the next twelve months.

Third Harmonic Bio reported its Q4 and year-end 2022 financial results, highlighting progress in preclinical development of a next-generation oral KIT inhibitor for mast cell-mediated inflammatory diseases. The company's cash and cash equivalents totaled $288.9 million as of December 31, 2022.

Third Harmonic Bio reported a net loss of $8.2 million for the quarter ended September 30, 2022. They completed an upsized initial public offering, providing funding through 2025, and patient dosing is underway in a Phase 1b chronic inducible urticaria clinical trial.